New fluorinated pyrrolidine and azetidine amides as dipeptidyl peptidase IV inhibitors
- 1 November 2005
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 15 (21) , 4770-4773
- https://doi.org/10.1016/j.bmcl.2005.07.026
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?Regulatory Peptides, 2005
- Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugsExpert Opinion on Investigational Drugs, 2005
- Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitusCurrent Opinion in Pharmacology, 2004
- GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 DiabetesHormone and Metabolic Research, 2004
- Therapeutic Strategies Based on Glucagon-Like Peptide 1Diabetes, 2004
- Dipeptidyl Peptidase IV Inhibitors for the Treatment of DiabetesJournal of Medicinal Chemistry, 2004
- Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2004
- 1-[[(3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic PropertiesJournal of Medicinal Chemistry, 2003
- Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of Type 2 diabetesExpert Opinion on Therapeutic Patents, 2003
- Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetesExpert Opinion on Investigational Drugs, 2003